Evaluación y Regulación: interfaz y flujo de la I+D de las nuevas moléculas
|
|
- Martin Watkins
- 5 years ago
- Views:
Transcription
1 Evaluación y Regulación: interfaz y flujo de la I+D de las nuevas moléculas César Hernández García Jefe de Departamento Medicamentos de Uso Humano Agencia Española de Medicamentos y Productos Sanitarios
2
3 Clinical Trials
4 CT Legislation Pharma Legislation Cross Border Directive (new proposal on HTA 2018) Transparency Directive Clinical Trials
5 CT Legislation Pharma Legislation Cross Border Directive (new proposal on HTA 2018) Transparency Directive Clinical Trials NCA Offices EU Innovation Network ITF Coordination and Support Action
6 CT Legislation Pharma Legislation Cross Border Directive (new proposal on HTA 2018) Transparency Directive Clinical Trials NCA Offices EU Innovation Network ITF Coordination and Support Action National SA Centralized SA Scientific Advice
7 CT Legislation Pharma Legislation Cross Border Directive (new proposal on HTA 2018) Transparency Directive Clinical Trials NCA Offices EU Innovation Network ITF Coordination and Support Action National SA Scientific Advice Centralized SA PRIME accelerate assessment EMA EPAR Conditional MA MA Exceptional Circumstances
8 CT Legislation Pharma Legislation Cross Border Directive (new proposal on HTA 2018) Transparency Directive Clinical Trials NCA Offices EU Innovation Network ITF Coordination and Support Action National SA Scientific Advice Centralized SA PRIME accelerate assessment EMA Parallel Consultation EUnetHTA EPAR Conditional MA MA Exceptional Circumstances EMA Committees Relative effectiveness assessment (REA)
9 CT Legislation Pharma Legislation Cross Border Directive (new proposal on HTA 2018) Transparency Directive Clinical Trials NCA Offices EU Innovation Network ITF Coordination and Support Action National SA Centralized SA PRIME Scientific Advice accelerate assessment Adaptive pathways Parallel Consultation EUnetHTA EPAR Conditional MA MA Exceptional Circumstances Relative effectiveness assessment (REA) Repurposing
10 CT Legislation Pharma Legislation Cross Border Directive (new proposal on HTA 2018) Transparency Directive Clinical Trials NCA Offices EU Innovation Network ITF Coordination and Support Action National SA Centralized SA PRIME Scientific Advice accelerate assessment Adaptive pathways Parallel Consultation EUnetHTA EPAR Conditional MA MA Exceptional Circumstances Relative effectiveness assessment (REA) Repurposing Registries Real World evidence
11 CT Legislation Pharma Legislation Standing Committee Cross Border Directive (new proposal on HTA 2018) Transparency Directive NCA Offices EU Innovation Network ITF Coordination and Support Action Ad hoc CT Expert Group CTFG National SA Centralized SA PRIME IMI projects Scientific Advice accelerate assessment EMA Clinical Trials Adaptive pathways Parallel Consultation EUnetHTA HMA and HMA Experts Groups (MAWP and 2020 Strategy) EPAR Conditional MA MA Exceptional Circumstances Safe and Timely Access to Medicines for Patients (STAMP) Expert Group Pharma Committee EMA Committees Relative effectiveness assessment (REA) Repurposing Registries Real World evidence
12 CT Legislation Pharma Legislation Standing Committee Cross Border Directive (new proposal on HTA 2018) Transparency Directive NCA Offices EU Innovation Network ITF Coordination and Support Action Ad hoc CT Expert Group CTFG National SA Centralized SA PRIME IMI projects Scientific Advice accelerate assessment EMA Synergy Group Clinical Trials EMA-EUnetHTA collaboration Adaptive pathways Parallel Consultation EUnetHTA HTA network HMA and HMA Experts Groups (MAWP and 2020 Strategy) EPAR Conditional MA MA Exceptional Circumstances Safe and Timely Access to Medicines for Patients (STAMP) Expert Group Pharma Committee EMA Committees Relative effectiveness assessment (REA) Repurposing Registries Real World evidence CAPR Network Project Euripid
13
14 Doce minutos algunas (3) ideas (algunas contracorriente)
15 recolocar los incentivos
16 Desarrollar nuevas estrategias para el desarrollo de medicamentos sin caer en la ingenuidad (lo cual no debe ser fácil, pero para que nos vamos a quedar con lo fácil)
17 Finalmente, o trabajamos juntos o seguimos como hasta ahora
18 GRACIAS
EU REA adoption at national level
EU REA adoption at national level Project scope and main findings January 2017 Agenda Project objectives and process Identification of barriers and potential solutions Conclusions 2 Project objectives
More informationAgenda item 4 - Real world evidence data collection. Italian Experience on Registries. Entela Xoxi
Agenda item 4 - Real world evidence data collection Italian Experience on Registries Entela Xoxi Commission expert group on "Safe and Timely Access to Medicines for Patients" (STAMP) Brussels, 10 March
More informationChallenges in Reimbursing Orphan Medicinal Products. Evaluating Benefit, Determining a Fair Price and Optimizing Access
Challenges in Reimbursing Orphan Medicinal Products Evaluating Benefit, Determining a Fair Price and Optimizing Access Acknowledgements This presentation reflects the work of colleagues at the Department
More informationStrengthening EU cooperation on health technology assessment
BRIEFING Initial Appraisal of a European Commission Impact Assessment Strengthening EU cooperation on health technology assessment Impact assessment (SWD(2018) 41 final, SWD(2018) 42 final (executive summary))
More informationSummaries of Risk Management Plan
Summaries of Risk Management Plan A transparency or a communication tool? Juan Garcia Burgos An agency of the European Union Risk Management EU legal basis First introduced in the legislation (Regulation
More informationTemplate for essential information to be provided for proposals including clinical trials / studies / investigations. Version 1.
Template for essential information to be provided for proposals including clinical trials / studies / investigations Version 1.1 1 February 2015 IMI2/INT/2015-00354 History of changes Version Date Change
More information5th Meeting of the Working Group on Relative Effectiveness
5th Meeting of the Working Group on Relative Effectiveness Brussels, 2 October 2007, 10.30 16.30 hrs Room 1 D, 1st floor, Centre de Conference Albert Borschette Note of the Meeting Chairs: Morning session:
More informationMaking the case for Horizon Scanning
Making the case for Horizon Scanning Facing the challenges: Equity, Sustainability and Access Aldo Golja, Beneluxa Coordinator Ministry of Health, The Netherlands 1 Introduction Samuel Becket bridge, Dublin
More informationRegulation of CDx under the new In Vitro Diagnostics Regulation
TOPRA Annual Medical Devices Symposium 2017 Regulation of CDx under the new In Vitro Diagnostics Regulation Challenges for Industry Peter Martin ENABLING AND PROMOTING EXCELLENCE IN THE HEALTHCARE REGULATORY
More informationProf. Francesco Saverio Mennini
Not reimburasable A STRUCTURED DEBATE REGARDING THE NATIONAL HEALTH ECONOMICS GUIDELINES IN SOUTHERN EUROPE Pharmaceutical Regulation and PhEconomics Guidelines in Italy Prof. Francesco Saverio Mennini
More informationPre-Accession Recommendations for Colombia
Pre-Accession Recommendations for Colombia These pre-accession recommendations for Colombia are provided as updates to the OECD and its member governments in the context of the ongoing accession reviews
More informationDisclosure Methodological Note For Aventis Pharma Ltd trading as Sanofi
Disclosure 2015 Methodological Note For Aventis Pharma Ltd trading as Sanofi INTRODUCTION The EFPIA Disclosure Code requires all EFPIA member companies to disclose transfers of value (TOV) such as support
More informationPre-Accession Recommendations for Colombia
Pre-Accession Recommendations for Colombia These pre-accession recommendations for Colombia are provided as updates to the OECD and its member governments in the context of the ongoing accession reviews
More informationSanofi-Aventis Bulgaria EOOD Methodological Note
Sanofi-Aventis Bulgaria EOOD Methodological Note INTRODUCTION Collaboration between healthcare professionals and Pharmaceutical Companies has long been a positive driver for advancements in patient care
More informationPharma Cooperation Code Transparency Report Methodological Note. Pfizer Switzerland
Pharma Cooperation Code Transparency Report 2017 Methodological Note Pfizer Switzerland 1. Table of Content 2. INTRODUCTION... 3 3. PFIZER ACTIVITIES PER EFPIA/SCIENCEINDUSTRIES CATEGORY... 4 4. DEFINITION
More informationEGA S COMMENTS ON THE CONCEPT PAPER ON THE INTRODUCTION OF FEES TO BE CHARGED BY THE EMA FOR PHARMACOVIGILANCE.
EGA S COMMENTS ON THE CONCEPT PAPER ON THE INTRODUCTION OF FEES TO BE CHARGED BY THE EMA FOR PHARMACOVIGILANCE. EGA S COMMENTS ON THE CONCEPT PAPER SUBMITTED FOR PUBLIC CONSULTATION ON THE INTRODUCTION
More informationEU PASS/PAES Requirements for Disclosure
EU PASS/PAES Requirements for Disclosure 10 th Industry Stakeholder Platform Operation of EU pharmacovigilance, London, 3 February 2017 Presented by Dr. Thomas Goedecke Inspections, Human Medicines Pharmacovigilance
More informationEn la siguiente le estamos enviando el contrato de nuestros servicios. Favor de llenar y firmar las áreas marcadas en amarillo.
3501 W. Vine St. Suite 523 Kissimmee, FL 34741 Estimado (a): En la siguiente le estamos enviando el contrato de nuestros servicios. Favor de llenar y firmar las áreas marcadas en amarillo. Nuestro objetivo
More informationINVESTORS MANUAL. Investors Manual
INVESTORS MANUAL Investors Manual Index pag. 4 5 7 8 9 10 11 12 13 14 14 15 15 16 16 Introduction How to save and what to save? How to build your portfolio with Housers? What kind of opportunities can
More informationThe withdrawal of Poly Implant Prosthèse (PIP) silicone gel breast implants from the market in March 2010 created headlines around the world.
27 August 2014 PIP: an update Background The withdrawal of Poly Implant Prosthèse (PIP) silicone gel breast implants from the market in March 2010 created headlines around the world. PIP implants, developed
More informationTax insight New regulations to the Free Zones Law
www.pwc.com.uy Tax insight New regulations to the Free Zones Law September 2018 On September 24 th, the Ex ecutive Power announced the approval of Regulatory Decree of the Free Zones Law (FZL), which had
More informationMathematically Connected Communities
Mathematically Connected Communities PARCC PBA Practice Test Items Algebra II Mathematics en Español Excerpted 3/2015 from PARCC Online Practice Tests www.parcconline.org Mathematical Practice Questions
More informationPfizer Hellas SA PRIMA/EFPIADisclosure Code Transparency Report
Pfizer Hellas SA PRIMA/EFPIADisclosure Code Transparency Report Methodological Note Malta 1. INTRODUCTION... 3 2. PFIZER ACTIVITIES PER EFPIA CATEGORY... 4 3. SOURCES OF INFORMATION... 6 4. DEFINITION
More informationEmerging Issues in Latin America
Emerging Issues in Latin America The International Pharmaceutical Regulatory and Compliance Congress and Best Practices Forum Brussels, June 6-7, 6 2007 Panel Gonzalo Cornejo, GlaxoSmithKline Hector Armengod,
More informationAssess record for 'Public Consultation on a possible revision of Council Directive 89/105/EEC ("Transparency Directive")'
Assess record for 'Public Consultation on a possible revision of Council Directive 89/105/EEC ("Transparency Directive")' Respondent profile Please indicate the type of organisation on behalf of which
More informationJOBS. Orientation Handbook
JOBS Orientation Handbook The Job Opportunities and Basic Skills (JOBS) Program The Job Opportunities and Basic Skills (JOBS) program helps Temporary Assistance for Needy Families (TANF) participants
More informationMerz Pharma GmbH & Co. KGaA. Methodological Note. Transfer of Value Disclosure Report Belgium for the Calendar Year 2017
Merz Pharma GmbH & Co. KGaA Methodological Note Transfer of Value Disclosure Report Belgium for the Calendar Year 2017 1 I) Introductory note Merz supports laws and obligations which promote transparency
More informationQuarterly National Accounts of Spain. Base 2010
24 August 2017 Quarterly National Accounts of Spain. Base 2010 Second quarter of 2017 Los datos contenidos en esta nota de prensa corresponden al día de su publicación (24/08/2017). Con fecha 2/10/2017
More informationST-1 Transición Energética a un Modelo Eficiente y Descarbonizado
ST-1 Transición Energética a un Modelo Eficiente y Descarbonizado Enhancing Financial Flows for Energy Efficiency Investments (EEFTG) Presentado por el Rapporteur de EEFTG & CEO de Peter Sweatman Cual
More informationAll Participants in Carpenters Health and Welfare Trust Fund for California
CARPENTER FUNDS ADMINISTRATIVE OFFICE OF NORTHERN CALIFORNIA 265 Hegenberger Road, Suite 100 P.O. Box 2280, Oakland, California 94621-0180 Tel. (510) 633-0333 (888) 547-2054 Fax (510) 633-0215 www.carpenterfunds.com
More informationComunicado N 9340 Ref.: Oferta de Compra de Barings BDC Inc. (BBDC) Código CVSA: Código CUSIP: 06759L103
F-9082205 Comunicado N 9340 Ref: Oferta de Compra de Barings BDC Inc (BBDC) Código CVSA: 93703 Código CUSIP: 06759L103 Buenos Aires, 10 de agosto de 2018 Sres Depositantes Tengo el agrado de dirigirme
More informationPfizer 2016 Disclosure Code Transparency Report
Pfizer 2016 Disclosure Code Transparency Report Methodological Note Pfizer Ireland 1. INTRODUCTION... 3 2. PFIZER ACTIVITIES PER EFPIA CATEGORY... 5 3. SOURCES OF INFORMATION... 7 4. DEFINITION OF THE
More informationMarket Access Strategy and Planning: Succeeding in the Age of Value-based Reimbursement
Market Access Strategy and Planning: Succeeding in the Age of -based Reimbursement Presented by: Michael J. Lacey, Senior Director, Strategic Consulting (Life Sciences) Date: March 01, 2017 Truven Health
More informationFollow-up of the report of the Consultative Expert Working Group on Research and Development: Financing and Coordination
EXECUTIVE BOARD EB140/21 140th session 21 November 2016 Provisional agenda item 8.5 Follow-up of the report of the Consultative Expert Working Group on Research and Development: Financing and Coordination
More informationLEO Pharma Global Methodological Note to EFPIA HCP/HCO Disclosure Requirements
LEO Pharma Global Methodological Note to EFPIA HCP/HCO Disclosure Requirements ALL LEO TRADEMARKS MENTIONED BELONG TO THE LEO GROUP 2/14 Contents 1 Introduction... 3 2 Purpose... 3 3 Terminology and Definitions...
More informationREQUEST FOR MEDICARE PRESCRIPTION DRUG COVERAGE DETERMINATION
SilverScript Insurance Company Empire Plan Medicare Rx P.O. Box 52425, Phoenix, AZ 85072-2425 REQUEST FOR MEDICARE PRESCRIPTION DRUG COVERAGE DETERMINATION This form is used by SilverScript Insurance Company,
More informationIIT Policy on Spin-off
IIT Policy on Spin-off P15 - IIT POLICY on SPIN-OFF Revision Description of Modification Approval 1 First Print 23/11/2010 Index CHAPTER I General Provisions pg. 1 Art. 1 IIT goals regarding promotion
More informationKenneth B. Shephard M.D.,P.A.
Kenneth B. Shephard M.D.,P.A. Diplomate American Board of Endocrinology, Diabetes and Metabolism. 1. PATIENT INFORMATION / INFORMACION DEL PACIENTE Patient Name: Nombre Del Paciente Home Address: Direccion
More informationMay Pharma & Life Science Get Together
May 2017 Pharma & Life Science Get Together Introduction Your contacts Monica Cohen-Dumani Partner Corporate Tax Patricia More Partner Indirect Taxes PricewaterhouseCoopers SA, Geneva Switzerland Phone:
More informationDEVELOPMENT OF A PENSION SIMULATOR AS A KNOWLEDGE MANAGEMENT TOOL BASED ON THE SIMULATION OF EXPERIENCES
DEVELOPMENT OF A PENSION SIMULATOR AS A KNOWLEDGE MANAGEMENT TOOL BASED ON THE SIMULATION OF EXPERIENCES Mirón Torres, Ricardo (1), Vázquez González, Edgar René (2) 1 [Licenciatura en Sistemas de Información
More informationAL MERCADO ALTERNATIVO BURSÁTIL (MAB) Zaragoza, 27 de junio de Hecho Relevante
AL MERCADO ALTERNATIVO BURSÁTIL (MAB) Zaragoza, 27 de junio de 2018 Pangaea Oncology, S.A. (en adelante, Pangaea o la Sociedad ), en cumplimiento de lo dispuesto en el artículo 17 del Reglamento (UE) nº
More informationReporting of Transfers of Value to HCPs and HCOs Methodological Note for Reporting of 2017 Data in 2018
Reporting of Transfers of Value to HCPs and HCOs Methodological Note for Reporting of 2017 Data in 2018 ASTRAZENECA LUXEMBOURG SA N 2002 2220 862 AM BRILL 7B LU-3961 EHLANGE LUXEMBOURG Contents 1. Introduction...
More informationTransfer of Value Disclosure Report as per National Legislation
Merz Pharmaceuticals GmbH Methodological Note Transfer of Value Disclosure Report as per National Legislation 1 I) Introductory note Merz supports laws and obligations which promote transparency around
More informationModerator: J van Loon,MSc Mapi. Advisor to the President, Head of International Affairs, HAS France
Comparing the challenges of comparative effectiveness Research in France, Italy and the Netherlands Current Situation and Perspectives Issue Panelists: F. Meyer, MD Advisor to President, France E. Xoxi,
More informationBuying a Real State Property Based on Two Possible Scenarios: Cash Payment and Payment by Installments. What's the Best Option?
Scientific Papers (www.scientificpapers.org) Journal of Knowledge Management, Economics and Information Technology Buying a Real State Property Based on Two Possible Scenarios: Cash Payment and Payment
More informationLEO Pharma Global Methodological Note to EFPIA HCP/HCO Disclosure Requirements
LEO Pharma Global Methodological Note to EFPIA HCP/HCO Disclosure Requirements ALL LEO TRADEMARKS MENTIONED BELONG TO THE LEO GROUP 2/14 Contents 1 Introduction... 3 2 Purpose... 3 3 Terminology and Definitions...
More informationInvesting on Human Development: More than Conditioning Cash Transfers. Woodrow Wilson Center September 25, 2008
Investing on Human Development: More than Conditioning Cash Transfers Woodrow Wilson Center September 25, 2008 Contents Appreciation for CCTs is growing in the world Basic design for CCTs Specific features
More informationReporting of Transfers of Value to HCPs and HCOs Methodological Note for Reporting of 2017 Data in 2018
Reporting of Transfers of Value to HCPs and HCOs Methodological Note for Reporting of 2017 Data in 2018 AstraZeneca Pharma Poland Sp. z o.o. 0000117902 Postepu 14, 02-676 Warsaw Contents 1. Introduction...
More informationMiddle/ Segundo Nombre
Organization: American Legion MN Please enter your information within the next 40 minutes * This online application is protected by a Secure Certificate Authority, which supports up to a TLS1.2 256 bit
More informationOFFICE OF POLICY, PROCEDURES, AND TRAINING James K. Whelan, Executive Deputy Commissioner
OFFICE OF POLICY, PROCEDURES, AND TRAINING James K. Whelan, Executive Deputy Commissioner Stephen Fisher, Assistant Deputy Commissioner Office of Procedures POLICY BULLETIN 16-29-SYS MEDICAID SEPARATE
More informationSuperseded. Revision of EudraVigilance access policy for medicines for human use. European Commission 30 July 2014
4 August 2014 EMA/759287/2009 Revision 1 Inspections and Human Medicines Pharmacovigilance Division Revision of EudraVigilance access policy for medicines for human use Draft It is now superseded by a
More informationOE3 Trust Funds Health. Security. Service.
OE3 Trust Funds Health. Security. Service. Operating Engineers Trust Funds 1600 Harbor Bay Parkway, Suite 200, Alameda, CA 94502-3035 P.O. Box 23190, Oakland, CA 94623-0190 (800) 251-5014 OE3trustfunds.org
More informationReporting of Transfers of Value to HCPs and HCOs Methodological Note for Reporting of 2017 Data in 2018
NV ASTRAZENECA SA BE 0400.165.679 110, rue Egide Van Ophemstraat B-1180 Brussels Belgium Reporting of Transfers of Value to HCPs and HCOs Methodological Note for Reporting of 2017 Data in 2018 Contents
More informationSummer School. Health benefit package according to a human rights-based approach. Standards of care at European case-law
Summer School Health benefit package according to a human rights-based approach. Standards of care at European case-law André den Exter denexter@law.eur.nl Outline Background and characteristics SHI &
More informationPresentación sobre herramientas financieras (FBT) para el estudio de Cancer de Mama en México
Presentación sobre herramientas financieras (FBT) para el estudio de Cancer de Mama en México Seminario Taller Sobre Costo Efectividad De Cancer de Mama en México México DF, 2-4 Febrero 2011 Jeremy Lauer,
More informationMethodological Note to HCP/HCO Disclosure Requirements in the LEO Group including specifications from LEO Pharma A/S Romania Repressentative Office
Methodological Note to HCP/HCO Disclosure Requirements in the LEO Group including specifications from LEO Pharma A/S Romania Repressentative Office ALL LEO TRADEMARKS MENTIONED BELONG TO THE LEO GROUP
More informationEMVO COM Expert Group Workshop Brussels 13. December 2016
EMVO COM Expert Group Workshop Brussels 13. December 2016 Flat Fee Cost Allocation Model Maarten Van Baelen dd/mm/yyyy Flat Fee Model: MAH vs. Manufacturers FMD: The costs of the repositories system shall
More informationLast update: Document reference: IMI2/INT/
Last update: 07.04.2017 Document reference: IMI2/INT/2017-00830 1 Contents 1 Legal and financial framework... 3 2 IMI partners and actitivities... 4 3 Factsheet - IMI at a glance... 5 4 Budgetary principles...
More informationStudy on better cross-border Cooperation for high-cost Capital investments in health
Study on better cross-border Cooperation for high-cost Capital investments in health Final Report Executive Summary November 2016 Written by Gesundheit Österreich Forschungs- und Planungs GmbH November
More informationQUESTIONS/ISSUES/COMMENTS RE Foreclosure Deferment Program AS AMENDED 2010
QUESTIONS/ISSUES/COMMENTS RE Foreclosure Deferment Program AS AMENDED 2010 Disclaimer: This document is for internal Public Trustee use only and not for public distribution. This is Carol Snyder's work
More informationStandardisation of Health and Social Services
Standardisation of Health and Social Services Position of the European Social Insurance Platform (ESIP) FINAL 14 July 2016 - 2 - About the European Social Insurance Platform (ESIP) The European Social
More informationGuidelines on common procedures and methodologies for the supervisory review and evaluation process (SREP) (EBA/GL/2014/13)
Guidelines on common procedures and methodologies for the supervisory review and evaluation process (SREP) (EBA/GL/2014/13) Esta guía define, para las autoridades supervisoras, un marco común de desarrollo
More informationThe Impact of Future Healthcare Reform on MedTech Communications
J. Robert Paulson President & CEO NxThera, Inc. The Impact of Future Healthcare Reform on MedTech Communications Perspectives From an Early-Stage Medical Device Company The Impact of Future Healthcare
More informationDISCLOSURE OF TRANSFERS OF VALUE TO HEALTHCARE PROFESSIONALS AND HEALTHCARE ORGANISATIONS
DISCLOSURE OF TRANSFERS OF VALUE TO HEALTHCARE PROFESSIONALS AND HEALTHCARE ORGANISATIONS METHODOLOGICAL NOTES Date of Issue: June 2017 Country Scope: Ireland Version: 1.0 CONTENTS INTRODUCTION... 4 CONTENT...
More informationANNEX ON GENERAL RULES APPLICABLE TO (LIFE AND NON-LIFE) INSURERS OPERATING IN SPAIN UNDER FREEDOM TO PROVIDE SERVICES OR RIGHT OF ESTABLISHMENT
ANNEX ON GENERAL RULES APPLICABLE TO (LIFE AND NON-LIFE) INSURERS OPERATING IN SPAIN UNDER FREEDOM TO PROVIDE SERVICES OR RIGHT OF ESTABLISHMENT The list set out below is not exhaustive, but rather intends
More informationImportant Notice from Northern California Plasterers Health & Welfare Trust Fund About Your Prescription Drug Coverage and Medicare
Northern California Plasterers Health and Welfare Trust Fund 4160 Dublin Boulevard, Suite 400, Dublin, CA 94568-7756 Toll Free: 1-(844) 663-8121 * Fax: 1-(925) 833-7301 Email: plasterersinfo@hsba.com DATE:
More informationHow to accelerate health product development for diseases of poverty
How to accelerate health product development for diseases of poverty Overview of a report from TDR, the Special Programme for Research and Training in Tropical Diseases, on how an R&D Fund could be set
More informationSTATEMENT OF NEED FOR EMERGENCY AMENDMENT OF BANKING REGULATION 5-MORTGAGE FORECLOSURE DISCLOSURE. Banking Regulation 5 is hereby amended as follows:
State of Rhode Island and Providence Plantations DEPARTMENT OF BUSINESS REGULATION Division of Banking 1511 Pontiac Avenue Buildings 68 and 69 Cranston, Rhode Island 02920 STATEMENT OF NEED FOR EMERGENCY
More informationMethodological Note to 2017 Disclosure Report for Aventis Pharma Limited Genzyme Therapeutics Limited and Sanofi Pasteur
Methodological Note to 2017 Disclosure Report for Aventis Pharma Limited Genzyme Therapeutics Limited and Sanofi Pasteur Job Bag: SAGB.SA.18.03.0294 Date of Preparation: March 2018 INTRODUCTION The European
More informationALL LEO TRADEMARKS MENTIONED BELONG TO THE LEO GROUP
Methodological Note to HCP/HCO Disclosure Requirements in the LEO Group including specifications from LEO Pharma A/S Hungarian Company representative Office ALL LEO TRADEMARKS MENTIONED BELONG TO THE LEO
More informationUsing Banks in the United States
Finanza Toolbox Materials Using Banks in the United States Are Banks Safe? Using banks in the United States is much safer than in some other countries. The Federal Deposit Insurance Corporation (FDIC)
More informationEstablishing a Clinical Trials Finance Facility
Establishing a Clinical Trials Finance Facility Finance and licensing proposal October 2008 Overview Market Assessment Traditional equity funding model for pharmaceutical R&D under systemic pressure because
More informationBERKELEY ENERGIA LIMITED. NEWS RELEASE 17 August 2018 LSE/BME/ASX: BKY HECHO RELEVANTE. Issue of shares, Performance Rights and Appendix 3B
BERKELEY ENERGIA LIMITED NEWS RELEASE 17 August 2018 LSE/BME/ASX: BKY HECHO RELEVANTE Berkeley Energia Limited ( Berkeley o la Sociedad ), en cumplimiento de lo previsto en el artículo 17 del Reglamento
More informationWork as it should be!
Work as it should be! LABOR FORMALIZATION POLICY Marcela Mosquera Vásquez Sub-Directorate of Labor Formalization and Protection Content 1. Formalization of Labor General Aspects 1.1 Cross-section of informality
More informationReporting of Transfers of Value to HCPs and HCOs Methodological Note for Reporting of 2017 Data in 2018
Reporting of Transfers of Value to HCPs and HCOs Methodological Note for Reporting of 2017 Data in 2018 AstraZeneca SA 000638901000 4 Theotokopoulou & Astronafton 151 15 Maroussi, Athens, Greece PV: 2290014.1
More informationInstitutional Verification Document
2018 2019 Institutional Verification Document Your 2018 2019 Free Application for Federal Student Aid (FAFSA) was selected for review in a process called verification. The law says that before awarding
More informationAnnual Review 2013/14
Litigation Authority Annual Review 2013/14 Forward Look for 2014/17 & Catherine Dixon Chief Executive, NHS Litigation Authority Welcome to the NHS LA s Annual Review for 2013/14 and Forward Look for the
More informationWe would like to welcome you to Rainbow Pediatrics! Please fill out all the attached paperwork and read the following office policies.
Pankaj Sanwal, M.D., F.A.A.P. & Vibha Sanwal, M.D., F.A.A.P. 21141 Sterling Avenue, Unit#1, Georgetown, DE 19947 1212 Savannah RD, Lewes, DE 19958 TEL: (302) 856 6967 FAX: (302) 855 0744 TEL: (302) 645-2241
More informationDependent Verification Packet
Student s Last Name First Name MI Last 4 of SS# Verification Type: V1 V4 V5 Table of Contents Verification of 2015 Income Information for Student Tax Filers... 2 A 2015 IRS Tax Return Transcript may be
More informationShadow Toll in Colombia *
Shadow Toll in Colombia * Received: September 22, 2015. Accepted: January 29, 2016 Juan David González Ruiz ** jdgonzalez@esumer.edu.co Sergio Botero Botero *** sbotero@unal.edu.co Carlos Alejandro Arboleda
More informationURUGUAY. Status of List of Reservations and Notifications at the Time of Signature
URUGUAY Status of List of Reservations and Notifications at the Time of Signature This document contains a provisional list of expected reservations and notifications to be made by Uruguay pursuant to
More informationTakeda Belgium - Methodological note 2015
Takeda Belgium - Methodological note 2015 Accompanying document for the public transparency of transfer of value to Healthcare Professionals and Healthcare Organisations 1. General introduction... 2 2.
More informationState Hearing Decision
OHIO DEPARTMENT OF JOB AND FAMILY SERVICES BUREAU OF STATE HEARINGS In the matter of: Case Number: County: 5055309800 DELAWARE Appeal: Program: Disposition: 1323071 MED SUSTAINED Compliance Required Decision
More informationIndependent Verification Worksheet V5
1 2018 2019 Independent Verification Worksheet V5 Your 2018 2019 Free Application for Federal Student Aid (FAFSA) was selected for verification. In this process we are required by law to compare the information
More informationDecision of the Dispute Resolution Chamber
Decision of the Dispute Resolution Chamber passed in Zurich, Switzerland, on 26 January 2011, in the following composition: Geoff Thompson (England), Chairman ad interim Gerardo Movilla (Spain), member
More informationchemed pharmacy AAA63B3145EDBC32F F Chemed Pharmacy 1 / 6
Chemed Pharmacy 1 / 6 2 / 6 3 / 6 Chemed Pharmacy Center for Health Education, Medicine, & Dentistry. With a team of carefully selected, quality providers and a comprehensive range of medical services,
More informationGUIDELINE ON THE PROCESSING OF RENEWALS IN THE CENTRALISED PROCEDURE
EUROPEAN COMMISSION ENTERPRISE AND INDUSTRY DIRECTORATE-GENERAL Consumer goods Pharmaceuticals Brussels, 19.12.2005 ENTR/F2/KK D(2005) Revision 2005 NOTICE TO APPLICANTS VETERINARY MEDICINAL PRODUCTS GUIDELINE
More informationUNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C FORM 8-K
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event
More informationREPORT on the annual accounts of the European Medicines Agency for the financial year 2010, together with the Agency s replies (2011/C 366/06)
15.12.2011 Official Journal of the European Union C 366/27 REPORT on the annual accounts of the European Medicines Agency for the financial year 2010, together with the Agency s replies (2011/C 366/06)
More informationChanges to the ABPI Code of Practice -
Changes to the ABPI Code of Practice - from a Medical Education & PR perspective For Network Pharma members Background European (EFPIA) Code updated in 2007 ABPI had to conform by 1st July Plus UK-specific
More informationReporting of Transfers of Value to HCPs and HCOs Methodological Note for Reporting of 2017 Data in 2018
AstraZeneca Eesti OÜ Reg. kood 11733875 Järvevana tee 9 11314 Tallinn Estonia Reporting of Transfers of Value to HCPs and HCOs Methodological Note for Reporting of 2017 Data in 2018 Contents 1. Introduction...
More informationReporting of Transfers of Value to HCPs and HCOs Methodological Note for Reporting of 2017 Data in 2018
AstraZeneca Latvija 40103252820 Skanstes iela 50, Rīga, LV-1013 Reporting of Transfers of Value to HCPs and HCOs Methodological Note for Reporting of 2017 Data in 2018 Contents 1. Introduction... 4 Approach
More informationEVIDENCE FOR DECISIONS ON HEALTH BENEFITS - ROLE OF HTA
Strategic Purchasing EVIDENCE FOR DECISIONS ON HEALTH BENEFITS - ROLE OF HTA Strategic Purchasing Meeting WHO, Geneva, May 2017 Mohamed Gad Technical Analyst- Health Economics, Global Health and Development,
More informationAstraZeneca AB Södertälje. Reporting of Transfers of Value to HCPs and HCOs Methodological Note for Reporting of 2017 Data in 2018
AstraZeneca AB 556011-7482 151 85 Södertälje Reporting of Transfers of Value to HCPs and HCOs Methodological Note for Reporting of 2017 Data in 2018 Contents 1. Introduction... 4 Approach to disclosure
More informationThe Landscape of Medicaid Value-based Purchasing
The Landscape of Medicaid Value-based Purchasing CSG Medicaid Policy Academy Sept. 22, 2016 Lindsey Browning Senior Policy Analyst Overview Background State Medicaid Landscape of Value-based Purchasing
More informationThe following is an explanation of why your drug is not covered or is limited under your plan.
Community Health Plan of Washington 720 Olive Way, Suite 300 Seattle, WA 98101 Dear : This letter is to inform you that Community HealthFirst
More informationMAKING IT EASY... TO GET WORKERS COMPENSATION PRESCRIPTIONS FILLED.
Optum PO Box 152539 Tampa, FL 33684-2539 MAKING IT EASY... TO GET WORKERS COMPENSATION PRESCRIPTIONS FILLED. Optum has been chosen to manage your workers compensation pharmacy benefits for your employer
More informationLA RESTRUCTURACIÓN DE LA DEUDA GRIEGA EN MANOS DEL SECTOR PRIVADO: PUNTO DE PARTIDA PROCESO Y RESULTADO
LA RESTRUCTURACIÓN DE LA DEUDA GRIEGA EN MANOS DEL SECTOR PRIVADO: PUNTO DE PARTIDA PROCESO Y RESULTADO Andrés de la Cruz Buenos Aires, 5 de diciembre de 2012 Slide 1 Slide 2 Slide 3 Slide 4 Slide 5 Slide
More informationIMI2 PROPOSAL TEMPLATE
IMI2 PROPOSAL TEMPLATE (TECHNICAL ANNEX) RESEARCH AND INNOVATION ACTIONS & INNOVATION ACTIONS Note: This is for information only. The definitive template for your call will be available in the submission
More informationLast First M.I. Student s CSU ID Number. City State Zip Code Preferred Address ( ) Relationship to Student
Verification Worksheet for Independent Students Your 2018 2019 Free Application for Federal Student Aid (FAFSA) was selected for review in a process called Verification. The U.S. Department of Education
More information